Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.77 |
| ▸ | AURKA | O14965 | 5/20 | 0.71 |
| ▸ | EGFR | P00533 | 8/20 | 0.70 |
| ▸ | BTK | Q06187 | 3/20 | 0.70 |
| ▸ | ITK | Q08881 | 3/20 | 0.70 |
| ▸ | JAK2 | O60674 | 1/20 | 0.70 |
| ▸ | LYN | P07948 | 1/20 | 0.70 |
| ▸ | TEC | P42680 | 1/20 | 0.70 |
| ▸ | TXK | P42681 | 1/20 | 0.70 |
| ▸ | BMX | P51813 | 1/20 | 0.70 |
| ▸ | JAK3 | P52333 | 1/20 | 0.70 |
| ▸ | CD69 | Q07108 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30150629 | 0.90 | SYK (0.77) | SYKAURKAEGFRBTKITK | |
| SCHEMBL29665636 | 0.90 | SYK (0.77) | SYKAURKAEGFRBTKITK | |
| SCHEMBL13166285 | 0.90 | SYK (0.77) | SYKAURKAEGFRBTKITK | |
| SCHEMBL23388258 | 0.90 | SYK (0.77) | SYKAURKAEGFRBTKITK | |
| SCHEMBL27020093 | 0.90 | SYK (0.77) | SYKAURKAEGFRBTKITK | |
| SCHEMBL23408964 | 0.89 | SYK (0.68) | SYKAURKAEGFRBTKITK | |
| SCHEMBL29665760 | 0.89 | SYK (0.75) | SYKAURKAEGFRBTKITK | |
| SCHEMBL27020262 | 0.89 | SYK (0.75) | SYKAURKAEGFRBTKITK | |
| SCHEMBL15814670 | 0.87 | EGFR (0.82) | SYKEGFRBTKITKJAK2 | |
| SCHEMBL25069031 | 0.87 | SYK (0.72) | SYKAURKAEGFRBTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2023-02-23 | — | — | US | disclosed |
| WO-2021099842-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC. (CA) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | FURIN, PFAS, CFTR | SYK 972/4885AURKA 3624/4885EGFR 308/4885 |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | ABCG2, ABCB1, ARSA | SYK 610/4885AURKA 2089/4885EGFR 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.